Abstract The aberrant accumulation of aggregated b-amyloid peptides (Ab) as plaques is a hallmark of Alzheimer's disease (AD) neuropathology and reduction of Ab has become a leading direction of emerging experimental therapies for the disease. The mechanism(s) whereby Ab is involved in the pathophysiology of the disease remain(s) poorly understood. Initially fibrils, and subsequently oligomers of extracellular Ab have been viewed as the most important pathogenic form of Ab in AD. More recently, the intraneuronal accumulation of Ab has been described in the brain, although technical considerations and its relevance in AD have made this a controversial topic. Here, we review the emerging evidence linking intraneuronal Ab accumulation to the development of synaptic pathology and plaques in AD, and discuss the implications of intraneuronal b-amyloid for AD pathology, biology, diagnosis and therapy.
Introduction
The anatomically selective and differential accumulation of Ab plaques and neurofibrillary tangles (NFTs) are neuropathological hallmarks of AD [193, 207] . Brains of those afflicted by AD are additionally characterized by agingrelated cerebral atrophy, loss of neurons, inflammation and typically also amyloid angiopathy. Although not routinely analyzed in clinical neuropathological examination of AD brains, research studies have reported that loss of synaptic markers, specifically of the pre-synaptic protein synaptophysin, is the best brain correlate of cognitive decline in AD [40, 42, 168, 184, 192] . Over the past two to three decades significant progress has been made in understanding the genetics, biology and pathology of AD [11, 44, 65, 148] . The short, hydrophobic, and up to 42/43 amino acid long Ab peptide has taken center stage in AD research, with the majority of emerging experimental therapies directed at reduction of cerebral Ab. Although traditionally viewed as causing only extracellular pathology, the past decade has provided increasing evidence for a critical role in the accumulation of Ab peptides within neurons.
Central role of Ab in Alzheimer's disease
The Ab peptide moved to the center of AD research when converging genetic, biological and pathological clues pointed to its importance. Specifically, all autosomal dominant mutations associated with rare familial forms of early onset AD in the amyloid precursor protein (APP) and presenilin (PS) 1 and 2 were shown to increase the proportion of Ab42 to Ab40 peptides. In addition, the added copy of APP in trisomy 21 was known to be associated with the early and invariable development of AD pathology in Down syndrome [52] . Moreover, familial AD (FAD) associated with triplication of wild-type APP was reported [153] . Current evidence argues against another APP cleavage product being more important than specifically the Ab42 isoform in AD. First, the location of FAD mutations in APP point to the role of Ab, since they localize either to the b-or c-cleavage sites in APP involved in Ab generation or within the Ab domain itself (Fig. 1) . Second, changes in other APP metabolites, such as the APP intracellular domain (AICD) and APP C-terminal fragments (CTFs) [161] , are not as consistent as the increased Ab42 to Ab40 ratio in FAD [71] . At the same time, the most important genetic risk factor for the development of AD is apolipoprotein E (apoE) [30, 166] . Present in humans as a combination of two apolipoprotein e2, e3 and/ or e4 alleles, it is specifically the e4 allele that markedly increases the relative risk for the development of AD. Although the biological mechanism(s) of apoE's involvement in the disease process is at a relatively early stage of understanding [17, 111] , apoEe4 has been consistently associated with increased cerebral Ab load [88] .
Notably, the slightly longer Ab42 species that is specifically linked with FAD is also the first Ab species deposited in cerebral plaques [82] . Interestingly, the earliest Ab42 in plaques appears to be N-truncated [98] . It is known that progressive N-truncation increases the propensity of aggregation [146, 165] and toxicity [23] , although the most important N-terminus of highly aggregable Abx-42 peptides in plaque formation remains unclear. In fact, a diverse set of N-and C-terminally truncated Ab peptides exist in the brain [131] . In addition, b-cleavage of APP normally generates both N-terminal AbAsp1 and Glu11 peptides [21, 59, 197] . Overall, data suggest that pyroglutamate Ab3-42 [68, 157, 206] and Ab11-42 [131, 155] , among others, might be particularly important in AD.
Additional support for the importance of Ab has come from therapeutic studies on AD transgenic mouse models. Experimental therapies, such as Ab immunotherapy [8, 53, 138, 164, 178] , were not only shown to reduce cerebral Ab, but even more importantly, to improve behavior in transgenic mouse models of AD-like cerebral b-amyloidosis. Whether such Ab-targeted therapies can also be effective in human AD, not consistently linked with elevated Ab production as AD transgenic mice, remains less clear [75, 176] .
At the same time, one needs to be vigilant about assigning too much of a role to one small peptide. Aging is considered the most important risk factor driving the development of AD. There are many hypotheses for aging that are also active areas of investigation in the field of AD research. Oxidative stress and mitochondrial dysfunction are considered to play major roles in aging and to promote the development of age-related neurodegenerative diseases [102, 104, 109, 144, 183] . Inflammation [128, 208] and the immune system [178] are also thought to modulate the and c-secretases, and domains recognized by representative antibodies. Ab/APP antibodies, such as 6E10 and 4G8, recognize full-length APP, CTFs and Ab. Antibodies P2-1 and 369 are directed against the N-and C-terminal regions of full-length APP, respectively. Antibody 3D6 is specific to the free N-terminus of Ab1-x and bCTF; this antibody will not recognize full-length APP or other APP CTFs. Antibodies MBC40 and MBC42 specifically recognize the free C-terminus of Ab40 and Ab42, respectively, and do not react against full-length APP or APP CTFs disease process and are under investigation for their role in AD.
The main constituent of NFTs, the microtubule-associated protein tau, has received somewhat less attention compared to Ab, mainly because tau pathology is less specific to AD than Ab pathology, and because research has shown that in human AD and transgenic mouse models of AD, tau follows Ab pathology rather than vice versa [60, 138] . Moreover, mutations in tau, rather than associated with AD, have been linked with familial forms of frontotemporal dementia (FTD; [132] ), a less common form of dementia with a different clinical presentation and neuropathology that is not characterized by amyloid plaques. Evidence in experimental AD mouse models supports that Ab acts via tau, particularly in promoting neurodegeneration [56, 101, 140, 151, 160] .
Current data suggest a hierarchy in the development of AD with aging, with emerging evidence increasingly supporting that AD begins with declining levels of Ab42 in cerebrospinal fluid (CSF) and accumulation of intraneuronal Ab42, although the precise steps linking Ab to synaptic dysfunction, cognitive decline and neurodegeneration remain to be determined.
Intraneuronal Ab in Alzheimer's disease
A few intriguing early studies using newly developed antibodies directed at Ab peptides had noted immunolabeling of some neurons and NFTs in the brain [4, 62, 80, 115] . It is important to understand that these pan-Ab antibodies directed at the Ab domain detect not only Ab peptides but also the normally much more abundant full-length APP, and additionally, other Ab-containing APP fragments, such as b-secretase cleaved APP bCTFs (Fig. 1) . Hereafter, pan-Ab antibodies will be referred to as Ab/APP antibodies. This reactivity of Ab/APP antibodies to APP has contributed to considerable misunderstanding with regards to the presence of intraneuronal Ab in the field. Widely used Ab/APP antibodies for detection of plaques should label all cells, since APP, in contrast to Ab, is normally present at relatively high levels in cells. Since cell biological studies in the late 1980s and early 1990s did not support the presence of intraneuronal Ab, labeling of neurons and tangles with Ab/APP antibodies was eventually ascribed to cross-reactivity with lipofuscin [7] or to an artifactual shared epitope with tau [4] . Furthermore, the wide use of well-established Ab/APP antibodies (such as 4G8 and 6E10) was optimized for plaque detection in diagnostic neuropathology, where short 3,3 0 -Diaminobenzidine (DAB)/peroxidase reaction times typically reveal minimal labeling next to plaques in AD brain. The subsequent development of antibodies directed at the free C-terminal ends of Ab40 or Ab42 [82] led to the ability to differentiate Ab from APP labeling, since such antibodies now did not label the Ab domain within APP as Ab/APP antibodies had done (Fig. 1) . In contrast, while antibodies to the free Asp1 N-terminus of Ab1-x do not cross-react with full-length APP, these antibodies (for example antibody 3D6) do still detect the 1st product of amyloidogenic APP processing, b-cleaved bCTFs, which has the same N-terminus as Ab1-x peptides [76] . Confocal microscopy of mouse [129] and human (Fig. 2) primary neurons in culture underscores the complexity and differences in subcellular labeling of APP and its various metabolites, including Ab.
In 1993 the first biological paper appeared on the presence of Ab within cells [201] . Subsequent work showed that particularly the disease-linked Ab42 peptide, rather than the more abundantly secreted Ab40 peptide, increased with differentiation and time in culture within clonal NT2 cells that can develop a neuron-like phenotype [174, 195] . In addition, marked up-regulation of newly generated intracellular Ab42 was reported following the treatment of cells with extracellular Ab1-42 [211] . AD transgenic mice showed physiological [32, 74, 77, 124] and neuritic alterations [22, 125] prior to plaques, shifting the emphasis from fibrillar Ab to soluble, and potentially intracellular, Ab42 oligomers. Similarly, biochemical studies on human AD brain indicated that the soluble pool of Ab42 correlated best with degree of cognitive loss [108, 118, 130] . Intriguing in vitro and in vivo studies showed that intraneuronal Ab1-42 was particularly neurotoxic [213] , although lack of plaque formation in intraneuronal Ab42 accumulating transgenic mice with concomitant neurodegeneration [36, 93] limited conclusions that could be drawn to the human disease, since pathological diagnosis of AD requires Ab plaques. An intracellular environment should be more favorable for allowing Ab aggregation, since intracellular organelles can have a lower pH, higher metal ion concentrations and provide a limited space. These and other considerations led to the hypothesis that the intracellular pool of Ab may be quite important in the disease process [69, 203] .
Intraneuronal Ab in brain by light microscopy Two publications appeared in January 2000 on the intraneuronal accumulation of particularly Ab42 by light microscopy within neurons of human brain. One of these [123] showed Ab42 positive non-pyramidal neurons near plaques in advanced AD brain, although on closer inspection nuclei are not evident in these neuron-like structures that most resemble NFTs. The other publication [60] studied intraneuronal Ab40 and Ab42 in Down syndrome, non-neurological controls, mild cognitive impairment (MCI) and mild, moderate and severe AD. This publication [137] . Confirmation for the presence of intraneuronal Ab was provided by a study that showed the disappearance of intraneuronal Ab in AD transgenic mice when Ab levels were reduced either by treatment with c-secretase inhibitor or by crossing the mice with BACE knockout mice [145] .
Intraneuronal Ab in brain by immuno-electron microscopy
Immuno-electron microscopy (immuno-EM) was utilized to determine the subcellular localization of Ab in neurons of the brain. Remarkably, neurons in normal wild-type mouse, rat and human brains showed localization of Ab42 primarily associated with endosomal organelles, often identifiable on electron micrographs as late endosomal multivesicular bodies (MVBs; [188] ). Importantly, Ab42 labeling was shown to be absent in neurons of APP knockout mouse brains and the monoclonal Ab42 antibody used (MBC42) was determined by Western blot to bind Ab42, but not Ab40, full-length APP or APP C-terminal fragments (CTFs). In addition, dual-immuno-EM further indicated that APP has a different subcellular localization (primarily Golgi apparatus) compared to Ab42 (primarily endosomes). Endosomal Ab42 labeling by immuno-EM has since been confirmed by other groups [49, 95, 143] . In addition, Ab42 labeling in endosomes was reported in neurons in culture [2, 154] and brain [24, 196] .
Consecutive immuno-EM for Ab42 in aging, Ab plaque-forming AD transgenic mice (Tg2576 harboring the FAD Swedish mutation [78]) during a time period known to show marked increases in brain Ab [86] but prior to plaques, revealed that Ab42 accumulated particularly in endosomes within distal axons and dendrites (neurites), and their pre-and post-synaptic compartments, where with marked accumulation it was, at times, directly associated with intraneuronal pathology [188] . Confirmatory data were obtained in human AD brain tissue. Moreover, a subsequent immuno-EM study demonstrated that intraneuronal accumulation of higher molecular weight Ab42 oligomers (antibody M16; [210] ) was invariably associated with neuritic degeneration, even prior to plaques, in vulnerable distal neurites and synaptic compartments in brains of AD transgenic mice and human AD [187] . These immuno-EM studies were the first to directly associate Ab with synaptic and neuritic damage in the brain.
Concerns about intraneuronal Ab accumulation in AD
Ab antibody specificity and immunostaining Although the presence of intraneuronal Ab accumulation has now been widely detected in brains of human Down syndrome and AD, and transgenic models of AD, skepticism persists. A major initial concern was that intraneuronal Ab42 labeling in the brain was an artifact. There are different aspects to this concern. Many investigators, including clinical neuropathologists, did not appreciate intraneuronal Ab immuno-labeling in postmortem AD brains. Not seeing intraneuronal Ab in brain can be due to many factors other than its absence. In diagnostic neuropathology, typically brief development times for DAB/ peroxidase reactions are used with Ab/APP antibodies. This leads to ''clean'' plaque staining without ''background'', although as noted above, one should be aware that APP, in contrast to Ab, normally is an abundant protein in cells. Therefore, neurons should, and eventually do, stain with Ab/APP antibodies that also detect APP, if one uses appropriate immuno-histochemical procedures, including allowing for longer reaction times.
As noted above, the use of Ab/APP antibodies has been an issue in the acceptance of intraneuronal Ab. Some investigators inadvertently led to confusion by using such antibodies to describe intraneuronal Ab labeling in the brain. In the case of the triple transgenic mouse, the first transgenic mouse shown to develop both neuropathological hallmarks of the human disease, staining with an Ab/APP antibody was compared to that of an APP C-terminal antibody with an epitope outside of the Ab domain [140] . Since the APP antibody did not show similar intracellular accumulation, it was logical to conclude that it was Ab rather than APP that was accumulating. It is preferable to directly use Ab end-specific antibodies for determination of intraneuronal Ab, although it is important to be aware that not all C-terminal end-specific Ab40 and Ab42 antibodies are optimal. The quality of antibodies is of major importance, particularly for Ab detection. For example, it is not common knowledge that commercial antibodies can change. Particularly polyclonal antibodies can have batch to batch variations that can significantly affect interpretation. A significant development that further complicated interpretation of results with Ab antibodies was that of Ab antibody conformational specificity [87] . As Ab aggregates from monomers to oligomers and then fibrils, the conformation and antibody accessibility of peptide epitopes within Ab can change. Diverse new antibodies have been developed against different conformations of Ab. For example, C-terminal specific Ab42 antibodies typically are best at detecting Ab42 monomers, and have minimal reactivity against oligomers larger than trimers [187] . One also needs to be cautious when interpreting immunohistochemistry with antibodies against the N-terminus of Ab1-x peptides. Although these antibodies do not cross-react with full-length APP, they do also react against the same N-terminus on APP bCTFs. N-terminal Ab1-x/bCTFspecific antibodies also fail to label N-truncated Ab42 peptides that appear to be particularly important in AD [60, 98, 157, 158, 206] . Thus, the above caveats further underscore that the absence of labeling does not have to reflect absence of Ab within neurons. Detection of intraneuronal Ab is even more challenging in human brain, where in contrast to AD transgenic mice, APP is not over-expressed and FAD mutations that elevate Ab42 are rare. Moreover, intraneuronal Ab is best appreciated at early stages of pathology in AD transgenic mouse and human AD brains, while postmortem human AD brains are more often examined at end stages of disease. It should be noted that there is also variability in the degree of intraneuronal Ab labeling [60] , which is more pronounced in human compared to AD transgenic mouse brains. AD transgenic mice allow for considerably less variability, since not only can genetically identical mice be studied, but time to, and length of, fixation can be carefully controlled. Overall, detection of intraneuronal Ab can be challenging, and the use of complementary methods and APP knockout mice [214] are helpful controls. While there appeared to be an increase in intraneuronal Ab42 labeling with aging in AD vulnerable neurons in normal human brains, individual differences in neuroanatomical involvement and relative intensities of Ab40 compared to Ab42 labeling were noted [60] .
For example, particularly prominent intraneuronal Ab42 labeling was detected in the CA1 hippocampus in one young case of Down syndrome (3-year old; [60]) with concurrent tetralogy of Fallot (personal observations). Given the influence of, among others, head injury on APP metabolism and Ab deposition, coincident illness and agonal state likely contribute to variability of intraneuronal Ab labeling in human brain.
Additional concerns for the acceptance of intraneuronal Ab are applicable to all immuno-histochemical data. Postmortem interval, pre-treatments, counter-stains, fixation, and post-fixation, detergent and blocking solutions, all can influence interpretation of immuno-histochemistry, and also that of intraneuronal Ab [34, 39] . For a detailed protocol for Ab immunohistochemistry and immuno-electron microscopy see Gouras and Takahashi [57] .
Biochemical evidence on intraneuronal Ab accumulation
The relative dearth of recent biochemical evidence on intraneuronal Ab has contributed in delaying the acceptance of intraneuronal Ab. The aggregation-prone nature of Ab makes the accurate biochemical analysis of intraneuronal Ab particularly challenging. The limitation of a standard and widely used Ab assay was highlighted in a study using an enzyme-linked immunosorbent assay (ELISA) [181] . When the same amounts of Ab1-42 were incubated over time, levels of Ab42 assayed by a standard non-denaturing ELISA appeared to decline as a function of time, while denaturing Western blotting indicated that levels were actually unchanged; this occurred because ongoing Ab aggregation progressively blocked access of the Ab42 antibody in the ELISA. Furthermore, other biochemical Ab detection methods, such as immunoprecipitation, can vastly underestimate total Ab levels, since spiking of samples with a defined amount of Ab1-42 reveals that only a very small fraction of the added Ab can subsequently be detected (personal observations).
Biochemical determination of Ab levels in brain can also show considerable variation between studies. For example, the predominance of Ab40 compared to Ab42 in brain can vary, with some studies showing more and others less Ab42 than Ab40 in normal brain [131, 191] . It is particularly challenging to determine intra-compared to extra-cellular Ab in the brain using biochemical methods. Studies have increasingly differentiated between soluble and insoluble pools of Ab within the brain, where it is the increase in the soluble pool of Ab42 that tracks best with cognitive decline in AD [108, 118, 130] . Attempts have been made at further separating the soluble pool of Ab in the brain as soluble intracellular-enriched, membraneassociated or extracellular-enriched pools [100] , although the feasibility of separating these pools of Ab after brain homogenization, which breaks apart cell membranes, is questionable. It is intriguing to note that a recent study indicated that cognitive decline in AD tracked best with the membranous pool of Ab42 in brain tissue from human AD [180] ; it was concluded that this membrane-associated Ab42 was cell associated and reflected intraneuronal Ab42. Very interesting recent biochemical studies used laser capture microdissection combined with sensitive Ab ELISA to demonstrate elevated levels of Ab42 and an increased Ab42 to Ab40 ratio in both AD vulnerable CA1 hippocampal pyramidal and relatively AD resistant cerebellar Purkinje neurons both in familial and in sporadic AD compared to controls, although the amount of Ab42 was markedly higher in CA1 pyramidal compared to cerebellar Purkinje neurons in AD [5, 70] .
Ab in mitochondria
Another challenge for the acceptance of intraneuronal Ab accumulation were subsequent reports for different subcellular locations of accumulating Ab than endosomes, which included the plasma membrane [136, 209] and mitochondria [109] . In particular Ab localization to mitochondria has received considerable recent attention. There is a large group of investigators who have for years emphasized the importance of energy metabolism, oxidative stress and mitochondria in aging and AD. Thus, the localization of Ab to mitochondria was an exciting new link between their compelling prior work on the role of mitochondria in aging and AD with the peptide most linked with AD, and questions of how Ab might traffic to mitochondria were of less concern. APP trafficking and processing are not typically thought to involve mitochondria [159, 175, 194] . Overall, the data for the early accumulation of Ab in mitochondria appear weaker compared to that for endosomes. In fact, the initial study on Ab localization to mitochondrial [109] looked at much older AD transgenic mice with abundant plaques compared to studies on Ab in endosomes [188] . Nevertheless, Ab localization to mitochondria may still be quite important in AD pathogenesis. Thus, while aberrant Ab42 accumulation begins in endosomes, mitochondrial Ab may be a critical contributor in the pathological cascade leading to neuronal dysfunction and pathology in AD [33, 103, 149] . In fact, we have noted the presence, at times, of Ab-accumulating endosomes adjacent to mitochondria by immuno-EM (personal observations), which could suggest a link between endosomal and mitochondrial Ab [67] . At the same time, the role of mitochondria and oxidative stress in AD might be even more important upstream, rather than downstream, of Ab, since aging is the most important risk factor for Ab accumulation and AD. Indeed, elevated oxidative stress was reported to promote Ab plaques in the brains of AD transgenic mice [102] .
Familial AD mutations
It is widely thought that FAD mutations in APP or the presenilins cause increased secretion of Ab, although the common denominator among FAD mutations is not an increase in Ab secretion, but an increase in the Ab42 to Ab40 ratio [71] . It is less widely known that FAD mutations actually cause a relatively greater increase in intracellular compared to secreted Ab ( [202] , and unpublished observations). FAD mutations can even decrease secretion of the most abundantly released Ab isoform, Ab40, while still increasing the Ab42 to Ab40 ratio [90, 134, 173] . Emerging data from AD transgenic mice support that Ab40 might even be protective against cerebral amyloid [117] . The Arctic FAD mutation within the mid-region of Ab [133] primarily increase the propensity for Ab aggregation rather than secretion. In fact, FAD transgenic mouse models with the highest level of amyloidogenic Ab display particularly prominent early intraneuronal Ab accumulation [89, 106, 196] . Remarkably, a recent E693Delta mutation in APP was reported to be associated with an AD clinical phenotype in the absence of plaques; cells harboring this mutation were shown to have reduced Ab secretion and increased intracellular Ab accumulation and oligomerization [134] .
Relevance of intraneuronal Ab to AD pathogenesis
A concern that has been raised is that even if intraneuronal Ab42 accumulation does occur, it may be irrelevant to the disease. Emerging data, such as FAD mutations noted above, and the direct association of intraneuronal Ab42 with subcellular pathology [187, 188] , cell death [23, 167] , and behavioral and physiological abnormalities, even prior to plaques, in AD transgenic mouse models [140] , are providing increasing evidence for the importance of intraneuronal Ab. On the other hand, the apparent decrease in intraneuronal Ab42 with advancing plaque pathology noted in several initial reports on intraneuronal Ab accumulation [60, 64, 140, 205] , might suggest that while intraneuronal Ab accumulation is an early event, it is unlikely that it is the driving force in AD pathology, since in that case it should be progressive and correlate with cognitive decline. One possible explanation for this concern is that Ab aggregation leads to conformational changes and thereby the reduced ability of Ab antibodies in detecting their antigens. In fact, as noted above, standard Ab42 C-terminal end-specific antibodies typically are only optimal at detecting Ab42 monomers, and then lose their reactivity after dimers and trimers [187] . Another challenge is that the most marked accumulation of intraneuronal Ab42 occurs in distal neurites and synaptic compartments as determined by immuno-EM [188] that cannot be visualized effectively by light or standard immuno-fluorescence microscopy. It remains unclear whether and, if indeed the case, why cell body Ab42 by light microscopy seems to decline with AD progression in AD vulnerable neurons, such as CA1 pyramidal neurons, while by immuno-EM it continues to increase particularly within neurites and synapses [186] . It could, among other possibilities, be a combination of loss of Ab epitopes in cell bodies as Ab42 aggregates, increased synaptic Ab as cell body Ab declines, and even increased ability to degrade cell body compared to neurite-associated Ab42.
Many questions remain for the role of intraneuronal Ab in Alzheimer's disease Substantial questions remain for the role of intraneuronal Ab, and also for Ab in general, in AD pathogenesis. Notably, a subset of patients from the aborted Wyeth/ ELAN active Ab vaccine trial that was studied at autopsy showed Ab plaque removal in the absence of cognitive improvement [75] . This study has been highlighted as evidence against the importance of Ab in AD. Additionally, it remains unclear whether the decline in CSF Ab42 seen early in the conversion from normal to MCI and AD [48, 66] continues with progressive cognitive decline in AD. At the same time, increases in soluble Ab42 levels in the brain have been shown to track with decline in AD [108, 118, 130] . The combination of increasing soluble Ab42 in brain, declining CSF Ab42, and immuno-EM evidence of concomitant intraneuronal Ab42 accumulation, seem to strongly suggest that the soluble pool of Ab42 in the brain that correlates with disease progression mainly reflects intraneuronal Ab42. We note that one of the biochemical studies on soluble Ab42 levels correlating with AD progression [130] studied the same postmortem human brains analyzed in the initial immuno-histochemical study on intraneuronal Ab42 accumulation [60]. It will be important for future clinical-pathological studies to investigate for a correlation of biochemical and immunohistochemical data on intraneuronal Ab with cognitive decline. Additional correlation with levels of CSF Ab42 will also be important, particularly in individual AD patients over time, since population-based comparisons might fail to appreciate progressive changes, because of, for example, person-to-person differences in baseline levels of CSF Ab42.
A central question is why intraneuronal Ab42 increases in the first place. A more precise understanding of how aging and other injurious processes, such as cardiovascular disease or traumatic brain injury, can modulate Ab levels will be important. The mechanism, whereby intraneuronal Ab42 first adversely affects the biology of neurons is a central unanswered question. At the most basic level it seems that Ab42 could alter the normal function of endosomes near synapses. In one study, Ab-induced abnormalities in MVB endocytic sorting were demonstrated in APP mutant neurons, which appeared to be due to impairment of the ubiquitin proteasome system (UPS; [2] ). The role of extracellular Ab on intracellular Ab accumulation and plaque formation also remains unclear, as well as what proportion of intraneuronal Ab is derived from the inside compared to the outside of neurons.
Implications of intraneuronal Ab for Alzheimer's disease
Since accumulation of Ab42 within AD vulnerable neurons has been associated with physiological, pathological and behavioral abnormalities even prior to plaques [12, 140, 187, 188] , the evidence is mounting that intraneuronal Ab42 is the driving force in Ab-related AD pathogenesis [9, 58, 92] . Cumulative pathological data on intraneuronal Ab accumulation support a scenario of increased Ab42 in vulnerable distal neurites and synapses leading to their destruction from within (Fig. 3) . The subsequent formation of more amorphous plaques reflect remnants of this destruction further shaped by activated inflammatory cells. Reactive inflammatory cells and plaques may have both protective and detrimental roles that contribute to AD pathogenesis. It is possible that the localized and suddenly high levels of extracellular Ab42 following neuritic degeneration from within can then propagate Ab pathology to neighboring neurites via a prion-like ability of extracellular Ab42 [121] to up-regulate intracellular Ab42 [51, 58] . The lack of correlation between Ab plaques and cognitive decline in AD may relate to person-to-person differences in the ability of inflammatory cells to effectively remove Ab plaques from the brain. This scenario of Ab-related pathogenesis makes the cell biological study of the molecular and biological mechanism(s), whereby intraneuronal Ab accumulation leads to synaptic dysfunction of central importance. Intraneuronal Ab accumulation can also illuminate many ongoing questions and paradoxes in the field.
Pathology
Pathological relation between Ab, tau and synapses in Alzheimer's disease
The implications for intraneuronal Ab in AD include providing new insights into a link between Ab and tau pathologies that were formerly considered to be separate and how these two pathologies relate to synapse pathology [186] . By beginning within neurons, Ab is more directly accessible to altering tau, the principle component of the other neuropathological hallmark of AD. Specifically, immuno-histochemical data support that neuron cell bodies with early intraneuronal Ab42 accumulation are those that go onto develop NFTs [60, 140] , while their terminal fields are sites of early plaque pathology. An example of this is the early accumulation of Ab42 within layer II neuron cell bodies of the entorhinal cortex and early plaques at their axonal terminal fields in the outer molecular layer of the dentate in the hippocampus [60] . A more recent study investigated the subcellular link between intracellular Ab and tau pathologies [186] . It had been known that even in APP mutant transgenic mice hyperphosphorylated tau can be seen within some dystrophic neurites around plaques [14] . Since Ab42 accumulates within dystrophic neuritis [188] , Ab42 and phospho-tau were examined by dualimmunofluorescence and -EM in FAD mutant transgenic mouse and human AD brains. Remarkably, dystrophic neurites around plaques showed co-localization of phospho-tau with Ab42 in AD transgenic mice and human AD [186] . Since the triple transgenic mouse expressing mutant APP, PS1 and tau develops early Ab accumulation in CA1 hippocampal neurons and later tau paired helical filaments [140] , the stratum lacunosum-moleculare (SLM) of hippocampus containing the CA1 distal apical dendrites was selectively examined by immuno-EM. Remarkably, the SLM not only showed prominent early Ab42 increases but also the earliest labeling with antibodies against phosphotau, such as the well-established antibody AT8. By dualimmuno-EM phospho-tau was specifically evident in markedly Ab42 accumulating, distal CA1 apical dendrites and their post-synaptic compartments in the SLM [186] . Thus, tau, normally localized to axons, showed early mislocalization specifically in aberrant Ab42 accumulating distal dendrites. These data build on previous studies to provide an early temporal and spatial relationship of the main constituents of the two neuropathological hallmarks of AD and thereby also link them with synapse pathology in AD.
Additional evidence for synapses as sites of Alzheimer's disease pathology
Synapses have long been viewed as critical sites of AD pathology [6, 28, 112, 119, 168] and diverse evidence had supported that synapses are major sites of Ab pathology and also generation. Lesioning of the perforant pathway originating in the early AD prone entorhinal cortex leads to reduced plaque pathology at terminal synaptic fields in the hippocampus [96, 171] . In contrast, lesioning of another projection pathway, that from the locus coeruleus, was reported to increase plaque pathology in terminal fields of the cerebral cortex [72] . APP is transported down both axons and dendrites and Ab appears to be generated preferentially at synapses [25, 54, 85] . In fact synaptic activity was recently shown to promote APP transport down neurites to synapses [190] . Furthermore, extracellular Ab1-42 oligomers preferentially target synapses when added to neurons [43, 91] . Immuno-EM for PS1 localized this critical component of the c-secretase complex particularly to endosomes in distal neurites, including both in pre-and in post-synaptic compartments [94] . Indirect support for synapse-specific Ab generation also comes from PS1 conditional knockout mice, which showed aberrant accumulation of APP bCTFs in distal axons/pre-synaptic compartments [162] and also some anatomically selective accumulation in distal dendrites/post-synaptic compartments (personal observations).
Overall, emerging work on intraneuronal Ab is most consistent with the scenario of aging, and other genetic and environmental risk factors, such as apoEe4 and head injury, respectively, leading to up-regulation and then oligomerization of intraneuronal Ab42 in distal neurites and synapses, which then leads directly to destruction of neurites and synapses from within (Fig. 3) . Immuno-EM images of completely abnormal Ab42 accumulating dystrophic neurites [187, 188] , lacking the normal microtubule tracks required for organelle trafficking, secretion and exocytosis, argue against the active secretion of aggregating Ab42 from neurites prior to the dissolution of the plasma membrane [95] . Thus, the nidus of Ab plaques develops from within neurites at a time course that could also fit that of plaque formation determined by multiphoton microscopy (MPM) occurring within a day [120] . Remarkably, this MPM study of AD transgenic mouse brain in vivo also described the emergence of dystrophic neurites in areas distant from plaques that appeared and, at times, even disappeared, although intraneuronal Ab was not examined in these neurites. Plaque development in terminal processes can help explain the lack of neuron cell death in most AD transgenic mice in the presence of considerable plaque pathology, since neuron cell bodies can survive following loss of some neurites and synapses. At the same time, a subset of plaques appear to emerge directly from intracellular Ab accumulating neuron cell bodies [38, 60] . While Ab immuno-EM provides evidence for all forms of plaques, including diffuse plaques, representing destruction of neurites, there are several possible reasons for why degree of plaque pathology is not as good a measure of cognitive dysfunction compared to soluble, and we hypothesize intraneuronal, Ab42. Degree of intraneuronal Ab42 might tightly correlate with synaptic dysfunction, whereas synapse-independent factors might dissociate plaque burden from cognitive decline, for example, genetic heterogeneity may exist in the ability of inflammatory cells to remove plaques.
Head trauma and intraneuronal Ab
Intraneuronal Ab can provide new insights into head trauma as a risk factor for AD [116, 127] . Individuals, Acta Neuropathol (2010) 119:523-541 531 including children, who died following coma not long after severe head trauma were shown to develop amorphous cerebral Ab plaques [152] . At first this seems difficult to reconcile with recent data showing that patients in coma have marked reductions in extracellular Ab42, which rises and falls with cognitive improvement and decline, respectively [16] . We have observed marked up-regulation of intraneuronal Ab42 in surrounding neurites and neuron cell bodies near needle track injuries in rodent brains 48 to 72 h following brain injury (Fig. 4a) . By immuno-EM these increases in Ab42 occurred predominantly in endosomes (Fig. 4b) (Fig. 4c) .
Questions for intraneuronal Ab in Alzheimer's disease neuropathology
Many questions remain for the role of intraneuronal Ab in AD pathogenesis. It remains unclear whether and how Ab accumulation and pathology might differ in axons and presynaptic compartments compared to dendrites and postsynaptic compartments. Overall, more prominent increases in Ab42 accumulation were observed in distal dendrites compared to axons [188] , although there are anatomical differences, and it remains possible that either axons or dendrites are the initial site of intraneuronal Ab pathology.
Immuno-histochemical and -EM observations support that both distal and proximal dendritic arborizations are important sites of Ab42 accumulation and plaque formation (Fig. 3) . What determinants are involved in the selective vulnerability of certain neurons and their processes to Ab42 accumulation is another unanswered question. Differential anatomical levels of secretases [84] and chronic sites of synaptic activity [18] may be important in the selective c Dual-immuno-staining for Ab42 and AT8 (hyperphosphorylated tau) by light microscopy revealed Ab42 positive neurons (pink, black arrow), AT8 positive neurons (blue, white arrow) and also colocalization of Ab42 and AT8 within neurons (purple, arrow head) in postmortem brain from a case with dementia pugilistica. CA1 CA1 pyramidal cell body layer, SR stratum radiatum. Scale bars 100 lm (a, c); 2lm (b) vulnerability of AD. The cause of differences in plaque morphology and the involvement of inflammatory cells in plaque formation are also not fully clear [37] . In particular dense core plaques appear to be derived from neuron cell bodies, although even here it is possible that dendritic Ab42 accumulations are the inciting event. A recent report on in vitro plaque formation in cultured microglia [49] suggests the possibility that similar intracellular Ab accumulation and pathology as described in neurons might also occur in inflammatory cells in AD and thereby further contribute to plaque formation.
The involvement of the more abundantly secreted Ab40 in intraneuronal Ab accumulation and plaque formation is less clear. Although not apparently present in early Ab42 plaques as determined in Down syndrome [98] , Ab40 typically is the predominant peptide in amyloid angiopathy. An intriguing study showed that shifting the ratio of Ab42 to Ab40 in APP mutant transgenic mice under a neuron-specific promoter shifted the preponderance of parenchymal Ab42 plaques to vascular Ab40 amyloid [73] . This supports that amyloid angiopathy derives from perivascular drainage of Ab40 generated by neurons [61, 200] . Likewise, more Ab42 over-producing mice, by retaining Ab42 within neurites, can therefore be hypothesized to have less amyloid angiopathy.
Future comprehensive clinical-pathological studies that carefully compare and examine various intraneuronal Ab40 and Ab42 isoforms in different brain regions from cases with normal aging, mild cognitive impairment and different stages of AD, according to apoE genotype and intercurrent illness, and also in relation to neuropsychological testing, positron emission tomography (PET) amyloid and functional brain imaging, and CSF Ab levels, will be important to help clarify the role of intraneuronal Ab accumulation in AD [1] .
Biology
Aberrant accumulation of Ab within neurons in AD underscores the importance of uncovering the cellular and molecular mechanisms by which this pool of Ab leads to synaptic dysfunction. That this pathological accumulation is most prominent in distal neurites and synapses of AD transgenic mice provided the first direct association between Ab and synapse pathologies in the brain [188] . Since accumulating Ab42 localizes particularly to the outer limiting membrane of endosomes, and endosomes are known to reside near synapses [29] , altered function of these organelles [135] might be important for Ab-induced synaptic dysfunction. Fortuitously, it was possible to model intraneuronal Ab accumulation in cultured primary neurons derived from AD transgenic mice [187] . Comparing AD transgenic to wild-type neurons allowed for biological studies to begin elucidating early intraneuronal Ab-related abnormalities in neurons. Remarkably, APP mutant neurons showed differential alterations in synaptic proteins [3] that resembled those that have been described in AD brain, such as early loss of the pre-synaptic protein synaptophysin [113, 163, 192] and the post-synaptic protein PSD-95 [63] . It is of interest that among the earliest and most significantly Ab-altered synaptic proteins are AMPA glutamate receptor subunits [3, 79] , that are particularly important for synaptic plasticity.
In an effort to elucidate dysfunction of Ab-accumulating endosomes, a dynamic cell biological approach was used to compare APP mutant to wild-type neurons [2] . Using the well-established endocytosis of the epidermal growth factor receptor (EGFR), this study demonstrated that specifically the MVB sorting pathway, and not internalization or the recycling pathway, was altered in Ab accumulating neurons. The study went onto provide evidence that abnormalities in MVB sorting were due to Ab-dependent alterations in the ubiquitin-proteasome system (UPS). The UPS is increasingly being linked to neurodegenerative diseases of aging [10] . Best known for its role in degrading cytosolic proteins, the UPS also has important roles in synaptic plasticity [46] and lysosome-dependent degradation of trans-membrane proteins [105] .
An area of considerable interest has been how extracellular Ab alters synapses. Many in vitro and in vivo studies have shown that exogenous application of Ab alters synaptic plasticity [170, 198] and important synaptic proteins [3, 79, 177] , although how precisely this occurs remains unclear. Remarkably, it was shown that extracellular Ab1-42 was not toxic to APP knockout neurons [107] and that even point mutations in the NPXY motif in the C-terminus of APP block toxicity [169] . In addition, alterations of extracellular Ab on selective synaptic proteins mirrored those from intraneuronal Ab accumulation [3] . Recently, additional evidence pointed to the importance of amyloidogenic processing of APP, and therefore potentially intraneuronal Ab, in extracellular Ab-induced synapse dysfunction [190] . Work in the 1990s had shown that extracellular Ab1-42 led to marked up-regulation of endogenously generated Ab42 [51, 211] , which also occurs in neurons [190] . Although it is thought that only a small amount of extracellular can be internalized into neurons [156, 211] , Ab42 appears to a have a prion-like ability of transferring an altered aggregation state from the outside to the inside of cells [51] . It is possible that small amounts of extracellular Ab are internalized into neurons via APP at synapses, where extracellular Ab preferentially binds [91] and APP is enriched, particularly with synaptic activation [190] .
We are at an early stage of understanding the molecular mechanism(s), whereby accumulating Ab42 can alter normal synaptic function. Many questions remain next to figuring out the critical first step in intraneuronal Abinduced synaptic dysfunction. Elucidating the normal function of APP [199, 212] and probably even of Ab [147] are additionally of major interest.
Diagnosis
Recently it is becoming apparent that the earliest diagnostic change indicating that an individual without known cognitive deficits will go onto decline cognitively and develop AD is a drop in levels of Ab42 in the CSF [15, 48] . That the best predictor for conversion to MCI and then AD is a decrease in the levels of extracellular Ab42 might have seemed surprising to proponents of the prevalent extracellular Ab cascade hypothesis. The explanation put forward to keep these data in line with the extracellular Ab hypothesis was that high levels of extracellular Ab lead to progressive oligomerization and eventually plaque formation, with plaques then sequestering secreted Ab. There is a problem with this argument. It seems that the extracellular Ab hypothesis wants it both ways. On one hand, toxic extracellular Ab oligomers are thought to be released from plaques to damage nearby, although still physically removed, neurites, while on the other hand, extracellular Ab levels are supposed to be reduced because of increased sequestration to plaques. A more parsimonious and novel explanation, that is also in line with the Ab42 immuno-EM neuropathological data in brain and new insights relating to head injury described above, is that extracellular Ab42 declines because secretion of Ab42 is reduced as it accumulates instead within neurons.
At the same time, postmortem neuropathological studies and PET amyloid imaging indicate that individuals without known cognitive dysfunction can nevertheless have considerable plaque pathology. This has been used to argue that Ab and plaques are not themselves important for neurodegeneration [83] . One needs to be cautious with this interpretation, since considerable brain pathology can occur without detectable cognitive deficits. For example, relatively large strokes or tumors in strategic locations can fail to show deficits on bedside neurological examination. In fact, it is well known that most elderly patients will have signs of microvascular ischemic changes/damage on brain magnetic resonance imaging (MRI) even in the absence of known neurological deficits. Thus, microscopic Ab plaque pathology should also be able to go unnoticed, at least for a while. Furthermore, a recent imaging study supports that the presence of plaques by Pittsburgh compound B (PiB) PET amyloid imaging even in those diagnosed as cognitively normal does reflect deficits on functional imaging [179] . It needs to be stressed again that by immuno-EM high molecular weight Ab42 oligomers are consistently associated with pathology within neurites even prior to plaques [187] . Intraneuronal Ab42 accumulation, therefore, clearly can be detrimental already prior to plaques and obvious cognitive decline. One can even speculate that intracellular Ab contributes to the well-known normal agerelated decline in cognitive function that is accounted for by declining normative scores with age in neuropsychological testing. Similarly, intraneuronal Ab accumulation with advancing age may be important for what is termed benign forgetfulness of aging. The triple transgenic mouse supports the notion that elevated intraneuronal Ab can cause cognitive decline prior to plaques and tangles [12] .
Therapy
Most clinical trials now in progress, and even more that are planned, are targeted at reduction of brain Ab. Pharmacological inhibition of Ab generation by inhibiting b-or c-secretase has turned out to be more challenging than was originally hoped [13, 41] . Although reduction of the neuropathological hallmark and peptide most linked with the disease, Ab plaques and Ab peptides, is reasonable, a misunderstanding into the pathological role of Ab can have negative repercussions. For example, screening for small molecule chemical inhibitors of specifically Ab secretion could select compounds that are ineffective, and potentially even detrimental, for AD, since Ab secretion may not be harmful. The neuropathological and biological evidence on intraneuronal Ab accumulation increasingly suggest that this is the critical pool of Ab that needs to be contained. A recent neurobiological study showed that it was reduction of intraneuronal rather than extracellular Ab that correlated with synaptic improvement [190] . Remarkably, it was demonstrated that Ab antibodies can reduce the intraneuronal pool of Ab in vivo [138] and in vitro [189] , which for the latter was shown to require Ab antibody internalization. It is possible that the Wyeth/ELAN Ab vaccine trial failed precisely because it was not able to effectively reduce this critical pool of intraneuronal Ab. One can hypothesize that the abundant Ab in cerebral plaques might have sequestered the Ab antibodies and thereby prevented removal of the important intraneuronal pool of Ab. The concept that extracellular antibodies can be internalized and specifically alter intracellular proteins is not fully appreciated in clinical medicine and has therapeutic implications beyond AD.
Role of synaptic activity in Alzheimer's disease
Intraneuronal Ab can also illuminate a major current paradox in the field regarding the role of synaptic activity in AD. Synaptic activity has been shown to increase the secretion of Ab in hippocampal slices and living rodent brain [26, 85] . Furthermore, Ab secretion is also increased with cognitive activity, since patients in coma showed elevations in Ab with cognitive improvement; a subsequent decline in cognitive function correlated with decline in interstitial/extracellular Ab levels [16] . Hyperexcitability is present in AD brain [142] and epilepsy was shown to promote plaque pathology [110] . Accordingly, dampening of synaptic activity is under consideration for the treatment of AD. The Ab/synaptic activity paradox arises when one considers that cognitive activity is encouraged as potentially protective for patients with MCI and AD, and environmental enrichment was shown to reduce plaques in AD transgenic mice [55, 97] . Moreover, synaptic activity was recently shown to reduce the intraneuronal pool of Ab in vitro and in vivo [190] . Furthermore, functional brain imaging shows reduced resting brain activity in subjects with AD, and even in genetically at-risk subjects, decades prior to predicted cognitive symptoms [150] . Thus, reduced cerebral activity with AD should imply reduced Ab secretion in AD brain. The more widespread cortical activity seen by functional brain imaging in AD patients performing a specific task [122] could be used to argue for anatomical spread of extracellular Ab with disease progression to brain regions then with increased cortical activity and Ab secretion. Nevertheless, such task-specific spread in cortical activation is seen as a compensatory response with other brain injuries, and patients with AD would still be expected to have reduced cerebral activity most of the time. Another explanation for the potential Ab/synaptic activity paradox is that sites of high cerebral activity, in the default system, are indeed sites of early AD neuropathology [18, 179] , but not necessarily because of increased Ab secretion. Rather these sites of high metabolic activity also generate high levels of reactive oxygen species that might contribute to a progressively decreased ability to effectively degrade intraneuronal Ab42 with aging. The protease shown to most efficiently degrade Ab, neprilysin [81] , was reported to be critical in synaptic activity-induced intraneuronal Ab42 reduction [190] . Given that neprilysin localizes to synapses and declines with aging [20, 50] , declining neprilysin may be important in the age-related intraneuronal accumulation of Ab in synapses.
Conclusion
Reviews on AD have for years typically started with the statement: ''Alzheimer's disease is characterized by extracellular b-amyloid plaques and intracellular neurofibrillary tangles''. Emerging evidence on intraneuronal Ab strongly argues that this needs to change. Similar to tau aggregation developing within neurons but then as ghost tangles no longer within living neurons, Ab accumulation also begins intracellularly and ends up extracellular following neuritic degeneration. The intraneuronal origin of Ab plaques makes the pursuit of the neurobiology of Ab within neurons all the more important. AD is a tremendously complex disease that incorporates some of the most intricate processes that we know of: aging, memory and synapses. Finding more effective therapy for AD sooner may hinge on over-coming, but not just replacing, our own obstacles and dogmas, and pressing on with work to elucidate the molecular neuropathology and neurobiology of this most common neurodegenerative disease of aging. 
